Epstein barr virus treatment

Menu Search Home Diseases Chronic active Epstein-Barr virus infection. You can help advance rare disease research! This site is in-development and may not reflect the final version. Preview the new GARD site. Other Names:. Viral infections. Summary Summary. Symptoms Symptoms. These features may be different from person to person. Some people may have more symptoms than others and symptoms can range from mild to severe. This list does not include every symptom or feature that has been described in this condition.

Over time, CAEBV can lead to failure of the immune system which, if not treated, can lead to potentially life-threatening complications. Showing of 8 View All. Permanent enlargement of the airways of the lungs. Decreased immune function. Frequent respiratory infections. Multiple respiratory infections. Susceptibility to respiratory infections. Sinus inflammation. Increased spleen size. Do you have more information about symptoms of this disease?

We want to hear from you. Cause Cause. This allows the symptoms of an EBV infection to persist and get worse over time. Diagnosis Diagnosis. Treatment Treatment. Hematopoietic stem-cell transplant is currently the only curative treatment for this condition.

Statistics Statistics. Do you have updated information on this disease? Find a Specialist Find a Specialist. Healthcare Resources To find a medical professional who specializes in genetics, you can ask your doctor for a referral or you can search for one yourself. L-dioxolane thymidine derivatives were described as a potent class of anti-EBV agents and their anti-herpesvirus activity was dependent on viral TK.

Their antiviral activity proved to be dependent on phosphorylation by viral TK and by cytosolic TK1. The efficacy of both thionucleosides in mice against MHV acute infection was mostly promising for KAH, which showed similar in vivo potency as cidofovir. However, for those that do develop EBV-related illness there remains no directed small molecule therapy as antivirals used in clinical trials have been largely ineffective.

Past antiviral attempts have primarily targeted viral replication and further research into new avenues of study, including targeting non-replication proteins, may be necessary to develop effective therapy for EBV infections. EBV-triggered disease can cause debilitating illness and death and antiviral therapy targeting EBV for all related indications remains a major unmet medical need. National Center for Biotechnology Information , U.

Journal List Cancers Basel v. Cancers Basel. Published online Jun Joseph S. Whitehurst , 2 and Graciela Andrei 3. Christopher B. Author information Article notes Copyright and License information Disclaimer. Received May 9; Accepted Jun This article has been cited by other articles in PMC. Keywords: Epstein—Barr virus, maribavir, antiviral, acyclovir, ganciclovir.

Introduction Why is it that despite the profusion of drugs developed through the years that inhibit replication of the Epstein—Barr virus EBV their use clinically has been limited?

EBV Latency and Antivirals However, neither acyclovir nor other drugs have any effect on latent infection, which is dependent upon persistent EBV episomes, the circular form of EBV genome, not the encapsulated linear form [ 4 ]. Acyclovir and Infectious Mononucleosis Acyclovir is a nucleoside analog as are penciclovir, ganciclovir, and their oral prodrugs. Omaciclovir The carbocyclic nucleoside analog H2G, R [4-hydroxy hydroxymethyl butyl]guanine, omaciclovir, has potent activity against different herpesviruses, being particularly active against VZV [ 17 ].

Valomaciclovir The L-valine ester of H2G, i. Cidofovir Finally, there is some basis for using an antiviral drug in tumorous tissue. Thymidine Derivatives L-dioxolane thymidine derivatives were described as a potent class of anti-EBV agents and their anti-herpesvirus activity was dependent on viral TK. Funding This research received no external funding.

Conflicts of Interest The authors declare no conflict of interest. References 1. Tynell E. Acyclovir and prednisolone treatment of acute infectious mononucleosis: A multicenter, double-blind, placebo-controlled study. Pagano J. Perspectives on interactions of acyclovir with Epstein-Barr and other herpes viruses. Acyclovir and Epstein-Barr virus infection.

B — Colby B. Adams A. Epstein-Barr virus genomes with properties of circular DNA molecules in carrier cells. Gershburg E. Epstein-Barr virus infections: Prospects for treatment. Ernberg I. Acyclovir efficiently inhibits oropharyngeal excretion of Epstein-Barr virus in patients with acute infectious mononucleosis. Pt 10 J. Drebber U. The role of Epstein-Barr virus in acute and chronic hepatitis.

Negro F. The paradox of Epstein-Barr virus-associated hepatitis. Sakamoto Y. Tohoku J. Hocker B. Val- Ganciclovir prophylaxis reduces Epstein-Barr virus primary infection in pediatric renal transplantation. EBV can cause infectious mononucleosis , also called mono, and other illnesses. Many people become infected with EBV in childhood. EBV infections in children usually do not cause symptoms, or the symptoms are not distinguishable from other mild, brief childhood illnesses.

People who get symptoms from EBV infection, usually teenagers or adults, get better in two to four weeks. However, some people may feel fatigued for several weeks or even months. After you get an EBV infection, the virus becomes latent inactive in your body. In some cases, the virus may reactivate. This does not always cause symptoms, but people with weakened immune systems are more likely to develop symptoms if EBV reactivates. EBV spreads most commonly through bodily fluids, especially saliva.

However, EBV can also spread through blood and semen during sexual contact, blood transfusions, and organ transplantations. EBV can be spread by using objects, such as a toothbrush or drinking glass, that an infected person recently used. The virus probably survives on an object at least as long as the object remains moist. The first time you get infected with EBV primary EBV infection you can spread the virus for weeks and even before you have symptoms.

Once the virus is in your body, it stays there in a latent inactive state.